Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis

Blood GFAP as an emerging biomarker in brain and spinal cord disorders

(2022) Ahmed Abdelhak et al.   Nature Reviews Neurology

Serum Neurofilament Light and Multiple Sclerosis Progression Independent of Acute Inflammation

(2022) Arie R. Gafson et al.   JAMA Network Open

Multiple sclerosis: two decades of progress

(2022) Bruce A C Cree et al.   LANCET NEUROLOGY

Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study

(2022) Pascal Benkert et al.   LANCET NEUROLOGY

Blood Neurofilament Light in Progressive Multiple Sclerosis

(2022) David Leppert et al.   NEUROLOGY

Serum neurofilament light in MS: The first true blood-based biomarker?

(2021) Simon Thebault et al.   Multiple Sclerosis Journal

Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis

(2021) Robert J Fox et al.   Multiple Sclerosis Journal

Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker

(2021) Orhan Aktas et al.   ANNALS OF NEUROLOGY

Profiling serum neurofilament light chain and glial fibrillary acidic protein in primary progressive multiple sclerosis

(2021) James Giarraputo et al.   JOURNAL OF NEUROIMMUNOLOGY

The blood biomarkers puzzle – A review of protein biomarkers in neurodegenerative diseases

(2021) Christian Barro et al.   JOURNAL OF NEUROSCIENCE METHODS

Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MS

(2021) Jens Kuhle et al.   Multiple Sclerosis Journal

Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis

(2021) Claire Bridel et al.   NEUROLOGY

Secondary Progressive Multiple Sclerosis

(2021) Bruce A.C. Cree et al.   NEUROLOGY

Relationship Between Serum Neurofilament Light and Multiple Sclerosis Disability Progression: Clear as Mud

(2021) Carolyn Goldschmidt et al.   NEUROLOGY

Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis

(2021) Tomas Uher et al.   Multiple Sclerosis Journal

Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis

(2021) Heather Y. F. Yong et al.   Nature Reviews Neurology

A roadmap to precision medicine for multiple sclerosis

(2020) Tanuja Chitnis et al.   Multiple Sclerosis Journal

MAFG-driven astrocytes promote CNS inflammation

(2020) Michael A. Wheeler et al.   NATURE

Blood neurofilament light levels segregate treatment effects in multiple sclerosis

(2020) Bénédicte Delcoigne et al.   NEUROLOGY

Plasma neurofilament light levels are associated with the risk of disability in multiple sclerosis

(2020) Ali Manouchehrinia et al.   NEUROLOGY

Treatment of Multiple Sclerosis: A Review

(2020) Stephen L. Hauser et al.   AMERICAN JOURNAL OF MEDICINE

Serum neurofilament light as a biomarker in progressive multiple sclerosis

(2020) Raju Kapoor et al.   NEUROLOGY

The Role of Astrocytes in CNS Inflammation

(2020) Federico Giovannoni et al.   TRENDS IN IMMUNOLOGY

Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis

(2020) Simon Thebault et al.   Scientific Reports

Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity

(2020) Xavier Ayrignac et al.   Scientific Reports

Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials

(2020) Ludwig Kappos et al.   JAMA Neurology

Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?

(2019) Ahmed Abdelhak et al.   Frontiers in Neurology

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response

(2019) Jens Kuhle et al.   NEUROLOGY

Epidemiology and treatment of multiple sclerosis in elderly populations

(2019) Caila B. Vaughn et al.   Nature Reviews Neurology

Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD

(2019) Mitsuru Watanabe et al.   NEUROLOGY

Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years

(2019) Ester Cantó et al.   JAMA Neurology

Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis

(2018) Christian Barro et al.   BRAIN

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

(2018) Ludwig Kappos et al.   LANCET

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

(2018) Alan J Thompson et al.   LANCET NEUROLOGY

Multiple Sclerosis: Mechanisms and Immunotherapy

(2018) Clare Baecher-Allan et al.   NEURON

Multiple Sclerosis

(2018) Daniel S. Reich et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of sex hormones on immune function and MS development

(2018) María C Ysrraelit et al.   IMMUNOLOGY

Serum GFAP as a biomarker for disease severity in multiple sclerosis

(2018) A. Abdelhak et al.   Scientific Reports

Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity

(2018) Heidi Högel et al.   Multiple Sclerosis Journal

Neurofilament light chain serum levels correlate with 10‐year MRI outcomes in multiple sclerosis

(2018) Tanuja Chitnis et al.   Annals of Clinical and Translational Neurology

GFAP in early multiple sclerosis: A biomarker for inflammation

(2017) Rebecca Kassubek et al.   NEUROSCIENCE LETTERS

Defining secondary progressive multiple sclerosis

(2016) Johannes Lorscheider et al.   BRAIN

Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis

(2016) Lenka Novakova et al.   JOURNAL OF NEUROCHEMISTRY

Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis

(2016) M.Alba Mañé-Martínez et al.   JOURNAL OF NEUROIMMUNOLOGY

Pathological mechanisms in progressive multiple sclerosis

(2015) Don H Mahad et al.   LANCET NEUROLOGY

New Multiple Sclerosis Phenotypic Classification

(2014) Fred D. Lublin   EUROPEAN NEUROLOGY

Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis

(2014) Ilana Katz Sand et al.   Multiple Sclerosis Journal

Defining the clinical course of multiple sclerosis: The 2013 revisions

(2014) F. D. Lublin et al.   NEUROLOGY

Astrocytes: biology and pathology

(2009) Michael V. Sofroniew et al.   ACTA NEUROPATHOLOGICA

The challenge of multiple sclerosis: How do we cure a chronic heterogeneous disease?

(2009) Howard L. Weiner   ANNALS OF NEUROLOGY